Evaluation of docetaxel-loaded intravenous lipid emulsion: Pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity

Pharmaceutical Research

Volumn 27, Issue 8, 2010, Pages 1687-1702

  Zhao, Mingming ^a   Su, Min ^a   Lin, Xia ^a   Luo, Yanfei ^a   He, Haibing ^a   Cai, Cuifang ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

docetaxel; evaluation; lipid emulsion

Indexed keywords

DOCETAXEL; LIPID; ANTINEOPLASTIC AGENT; LIPID EMULSION; TAXOID;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TISSUE LEVEL; EMULSION; FEMALE; HEMOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MASS SPECTROMETRY; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RABBIT; RAT; SOLID TUMOR; TOXICITY TESTING; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG EFFECTS; EVALUATION STUDY; LONGITUDINAL STUDY; MOUSE; SAFETY; STANDARD; TISSUE DISTRIBUTION; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOGS; FAT EMULSIONS, INTRAVENOUS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MICE; RABBITS; RATS; RATS, WISTAR; REFERENCE STANDARDS; SAFETY; TAXOIDS; TISSUE DISTRIBUTION;

EID: 77955472037     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0180-0     Document Type: Article

References (31)

1. SJ Clarke LP Rivory 1999 Clinical pharmacokinetics of docetaxel Clin Pharmacol Ther. 36 99 114
2. J Verweij M Clavelf B Chevalier 1994 Paclitaxel (Taxol™) and docetaxel (Taxotere™): not simply two of a kind AnnOncol. 5 495 505
3. S Drori GD Eytan YG Assaraf 1995 Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alteration in membrane fluidity leading to increased membrane permeability Eur J Biochem. 228 1020 9 10.1111/j.1432-1033.1995.tb20352.x 7737146
4. M Ceruti V Tagini V Recalenda S Arpicco L Cattel M Airoldi, et al. 1999 Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions Il Farmaco. 54 733 9 10.1016/S0014-827X(99)00092-0 10668172 (Pubitemid 30009663)
5. ML Immordino P Brusa S Arpicco B Stella F Dosio L Cattel 2003 Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel J Control Release 91 417 29 10.1016/S0168-3659(03)00271-2 12932719 (Pubitemid 36980659)
6. Kim J-S, Kim NH, Lee NK, Lee JY, Jang WJ, Oh JG, et al. Stable Pharmaceutical Composition Containing Docetaxel and a Method of Manufacturing the same, Vol. WO2007136219, KR, 2007.
7. B Liu M Yang R Li Y Ding X Qian L Yu, et al. 2008 The antitumor effect of novel docetaxel-loaded thermosensitive micells Eur J Pharm Biopharm. 69 527 34 10.1016/j.ejpb.2008.01.015 18359617
8. K Gao J Sun K Liu X Liu Z He 2008 Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel Drug Dev Ind Pharm. 34 1227 37 10.1080/03639040802005057 18720137
9. T Musumeci CA Ventura I Giannone B Ruozi L Montenegro R Pignatello, et al. 2006 PLA/PLGA nanoparticles for sustained release of docetaxel Int J Pharm. 325 172 9 10.1016/j.ijpharm.2006.06.023 16887303 (Pubitemid 44573694)
10. M Takenaga 1996 Application of lipid microspheres for the treatment of cancer Adv Drug Deliv Rev. 20 209 19 10.1016/0169-409X(95)00124-P (Pubitemid 26284163)
11. V Venkateswarlu RR Patlolla 2001 Lipid microspheres as drug delivery systems Ind J Pharm Sci. 63 450 8
12. RH Muller S Schmidt I Buttle A Akkar J Schmitt S Bromer 2004 Solemuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs Int J Pharm. 269 293 302 10.1016/j.ijpharm.2003.09.019 14706241 (Pubitemid 38045293)
13. Santos LER, Colhone MC, Daghastanli KRP, Stabeli RG, Silva-Jardim I, Ciancaglini P. Lipid microspheres loaded with antigenic membrane proteins of the Leishmania amazonensis as a potential biotechnology application. J Colloid Interf Sci (2009).
14. M Singh IJ Ravin 1986 Parenteral emulsions as drug carrier systems JParenterSciTechnol. 40 34 41
15. L Wang H He X Tang R Shao D Chen 2006 A less irritant norcantharidin lipid microspheres: formulation and drug distribution Int J Pharm. 323 161 7 10.1016/j.ijpharm.2006.05.060 (Pubitemid 44397374)
16. LZ Wang BC Goh ME Grigg SC Lee YM Khoo HS Lee 2003 A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma Rapid Commun Mass Spectrom. 17 1548 52 10.1002/rcm.1091 12845579
17. CW Lee DH Hong SB Han S-H Jung HC Kim RL Fine, et al. 2002 A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2, 3-dihydro-1H-indol-6- sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models Biochem Pharmacol. 64 473 80 10.1016/S0006-2952(02)01105-X 12147299 (Pubitemid 34874850)
18. S Henkelman G Rakorst J Blanton W van Oeveren 2009 Standardization of incubation conditions for hemolysis testing of biomaterials Mat Sci Eng C. 29 1650 4 10.1016/j.msec.2009.01.002
19. S Shi H Chen X Lin X Tang 2010 Pharmacokinetics, tissue distribution and safety of cinnarizine delivered in lipid emulsion Int J Pharm. 383 264 70 10.1016/j.ijpharm.2009.09.025 19770029
20. C Zhang G Qu Y Sun X Wu Z Yao Q Guo, et al. 2008 Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel Biomaterials 29 1233 41 10.1016/j.biomaterials.2007.11. 029 18093646
21. L He G Wang Q Zhang 2003 An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile Int J Pharm. 250 45 50 10.1016/S0378-5173(02)00478-7 12480272 (Pubitemid 35447936)
22. K-i Hayashi T Ishikawa T Yamashita T Tajima K Nakayama 2003 Biphasic response of cutaneous blood flow induced by passive cutaneous anaphylaxis in rats Eur J Pharmacol. 482 305 11 10.1016/j.ejphar.2003.09.046 14660036 (Pubitemid 37505957)
23. M Kaszkin-Bettag A Richardson R Rettenberger PW Heger 2008 Long-term toxicity studies in dogs support the safety of the special extract ERr 731 from the roots of Rheum rhaponticum Food Chem Toxicol. 46 1608 18 18267351
24. L Zhao Y Wei X Zhong Y Liang X Zhang W Li, et al. 2009 and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations J Pharm Biomed Anal. 49 989 96 10.1016/j.jpba.2009.01. 016 19232851
25. MC Bissery G Nohynek GJ Sanderink F Lavelle 1995 Docetaxel (Taxotere):a review of preclinical and clinical experience. Pt I: preclinical experience Anticancer Drugs 6 339 55 10.1097/00001813-199506000-00001 7670132
26. C Gaillard B Monsarrat M Vuilhorgne I Royer B Monegier S Sable, et al. 1994 Docetaxel (Taxotere) metabolism in the rat in vivo and in vitro Proc Am Assoc Cancer Res. 35 428
27. A Sparreboom O van Tellingen WJ Nooijen JH Beijnen 1998 Preclinical pharmacokinetics of paclitaxel and docetaxel Anticancer Drugs 9 1 17 10.1097/00001813-199801000-00001 9491787 (Pubitemid 28088174)
28. A Tran V Jullien J Alexandre E Rey F Rabillon V Girre, et al. 2006 Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms Clin Pharmacol Ther. 79 570 80 10.1016/j.clpt.2006.02.003 16765145 (Pubitemid 43833447)
29. MC Bisseryl 1995 Preclinical pharmacology of docetaxel Eur J Cancer 31 S1 6 10.1016/0959-8049(95)00357-O
30. RR Patlolla V Vobalaboina 2005 Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion J Pharm Sci. 94 437 45 10.1002/jps.20249 15614812 (Pubitemid 40293338)
31. S Andre MC Bissery JF Riou M Bayssas NL Bail F Lavelle 1993 Docetaxel (RP56976, NSC628503): current status of development Cell Pharmacol. 1 S67 71